Genocea Biosciences Inc.

Plus Integra’s Caruso passes away and updates from Ambrx, Cullinan, Zephyr, South Rampart and more

Bleeding continued in biopharma in second quarter, with median market caps down in all tiers

Plus Alvotech’s Stelara biosimilar demonstrates bioequivalence and updates from uniQure, CSL, Alpine and more

Plus Kush, Haddach join RayzeBio and updates from Coherus, InterVenn, AsherBio and more

Improved antivirals, antibodies, vaccines and possible cures enter the horizon

Plus CEO Sandanayaka shifts to CSO at Nirogy, and updates from Angelini, Apie, 

Genocea shows targeting inhibitor neoantigens can abrogate vaccine-mediated protection

The next act for neoantigens includes cell therapies and a broader range of targets